文献速递胸部肿瘤放疗姑息放疗与转移瘤

原发灶生物有效剂量升高与寡转移性非小细胞肺癌生存改善相关

Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC.
PubMed 文献 · Radiother Oncol · 2021-08-19

中位随访55.1个月,原发灶BED(α/β=10)中位74.3 Gy。单因素和多因素分析显示,原发灶BED≥75 Gy与更好的局部控制、无进展生存和总生存相关。

要点

  • 原发灶BED≥75 Gy组中位PFS 12.8个月,BED<75 Gy组8.5个月(p<0.001)。
  • 原发灶BED≥75 Gy组中位OS 27.5个月,BED<75 Gy组22.9个月(p=0.02)。
  • 多因素分析中原发灶BED仍是OS(p=0.02)和PFS(p=0.002)的显著预测因素。

核心结论

  • 对同步寡转移性NSCLC患者,原发灶放疗BED>75 Gy与局部控制、PFS和OS改善相关。

研究设计与样本

  • 采用单因素和多因素Cox比例风险回归分析LRFS、PFS和OS的关联因素。

主要发现

  • 全队列中位随访55.1个月,中位PFS 11.0个月,中位OS 25.3个月。
  • 原发灶放疗BED(α/β=10)中位值为74.3 Gy。
  • 单因素分析:BED升高与PFS改善(p<0.001)和LRFS改善(p=0.01)相关;BED<75 Gy vs ≥75 Gy的中位PFS为8.5 vs 12.8个月,中位LRFS为23.4 vs 58.4个月。
  • 单因素分析:BED升高与OS改善相关(p=0.02);BED<75 Gy组中位OS 22.9个月,≥75 Gy组27.5个月。
  • 多因素分析:原发灶BED仍是OS(p=0.02)和PFS(p=0.002)的显著预测因素。

临床怎么用

  • 在寡转移性NSCLC的原发灶巩固放疗中,可考虑给予BED(α/β=10)≥75 Gy的剂量方案以改善局部控制与生存。
  • 该结果支持近期前瞻性试验结论,但需结合患者具体情况个体化决策。

局限性

  • 未报告多因素分析中LRFS的结果及其他潜在混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Local consolidative therapy (LCT) for oligometastatic non-small cell lung cancer (NSCLC) is an evolving treatment paradigm. We investigated whether the biologically effective dose (BED) of consolidative radiation therapy (RT) to the primary tumor predicted for improved local control, progression-free survival (PFS), and overall survival (OS) among NSCLC patients presenting with oligometastatic disease. MATERIALS AND METHODS: Patients presenting to a single institution (2000-2017) with stage IV NSCLC, ≤3 synchronous metastatic lesions at diagnosis, and treated with RT to the primary tumor were identified. Univariate and multivariable Cox proportional-hazards regression modeling were performed to identify factors associated with local recurrence-free survival (LRFS), PFS, and OS. RESULTS: One hundred twenty-four patients were identified meeting our inclusion criteria. With a median follow-up of 55.1 months, median PFS and OS for the entire cohort were 11.0 months and 25.3 months, respectively. The median BED (α/β = 10) of RT to the primary tumor was 74.3 Gy. On univariate analysis, increased BED to the primary tumor predicted for improved PFS (p < 0.001) and LRFS (p = 0.01), with a median PFS of 8.5 vs 12.8 months and median LRFS of 23.4 vs 58.4 months between patients treated with BED < 75 Gy and ≥75 Gy, respectively. Increased BED to the primary tumor was also associated with significantly improved OS (p = 0.02); patients treated with a BED of <75 Gy demonstrated a median OS of 22.9 months vs 27.5 months if treated with BED ≥ 75 Gy. On multivariable analysis, primary site BED remained a significant predictor of OS (p = 0.02) and PFS (p = 0.002). CONCLUSIONS: We found that delivery of >75 Gy BED RT regimens to the primary lesion in patients with synchronous oligometastatic NSCLC is associated with improved local control, PFS, and OS. These data support results of recent prospective trials and other ongoing prospective efforts to characterize therapeutic benefits associated with this management strategy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Farooqi A, Ludmir EB, Mitchell KG, et al. Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. Radiother Oncol. 2021. PMID: 34419505. doi:10.1016/j.radonc.2021.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。